More than 2 million Americans have Inflammatory Bowel Diseases (IBD), including Crohn’s Disease or Ulcerative Colitis. Although tuberculosis is uncommon in the United States, patients with IBD are at an increased risk for active tuberculosis infection due to the immunosuppressant therapies used to treat IBD. Due to this risk, testing for latent tuberculosis is recommended prior to and intermittently throughout administration of most IBD medications. The utility of this practice in a country with a low incidence and prevalence of tuberculosis is unknown.